NRIX Stock Price, Chart, Stats & News
NRIX chart
Fundamentals
Gross margin | -87.41% |
Operating margin | -340.16% |
Pretax margin | -314.00% |
Net margin | -314.90% |
Effective tax rate | -0.29% |
ROA | -38.43% |
ROE | -57.51% |
D/E | 0.10x |
Interest coverage ratio | – |
NRIX valuation
P/E | – |
P/S | 15.23x |
P/B | 2.61x |
P/CF | -5.63x |
P/FCF | -4.86x |
P/OCF | -5.63x |
PEG | 2.25x |
EV multiple | -5.72x |
About
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
Similar securities
Based on sector and market capitalization
